# Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation

> **NCT06705062** · PHASE3 · RECRUITING · sponsor: **Shanghai Jiao Tong University School of Medicine** · enrollment: 316 (estimated)

## Conditions studied

- Allogeneic Hematopoietic Cell Transplant
- Graft Versus Host Disease

## Interventions

- **DRUG:** reduced-dose PTCy
- **DRUG:** Standard dose PTCY

## Key facts

- **NCT ID:** NCT06705062
- **Lead sponsor:** Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-01
- **Primary completion:** 2027-12-01
- **Final completion:** 2028-07-01
- **Target enrollment:** 316 (ESTIMATED)
- **Last updated:** 2026-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06705062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06705062, "Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06705062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*